Published on
June 1, 2026
In the media
The Guardian: ‘I was getting ready to say goodbye’: cancer patient’s hope after smart drug success
About TV Therapeutics
TV Therapeutics is a clinical-stage biotech company advancing novel antigen modulation TVs for cancer and autoimmune diseases.
The company’s first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly.
TV’s oncology TV (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating durable clinical responses across multiple tumor types. The company’s autoimmunity TV (GRWD0715) is progressing in a Phase 1/2 trial to treat the source of axial spondyloarthritis ahead of a planned expansion into other autoimmune indications.
TV is headquartered in Oxford, UK.
More information: Website |
Media enquiries
Patrick White, Head of Communications
